- CITATIONS: 1
|Application ||WB, IHC-P, FC, E|
|Calculated MW||63342 Da|
|Antigen Region||214-242 aa|
|Other Names||TOX high mobility group box family member 3, CAG trinucleotide repeat-containing gene F9 protein, Trinucleotide repeat-containing gene 9 protein, TOX3, CAGF9, TNRC9|
|Target/Specificity||This TOX3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 214-242 amino acids from the Central region of human TOX3.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||TOX3 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Transcriptional coactivator of the p300/CBP-mediated transcription complex. Activates transactivation through cAMP response element (CRE) sites. Protects against cell death by inducing antiapoptotic and repressing pro-apoptotic transcripts. Stimulates transcription from the estrogen-responsive or BCL-2 promoters. Required for depolarization-induced transcription activation of the C-FOS promoter in neurons. Associates with chromatin to the estrogen-responsive C3 promoter region.|
|Tissue Location||Expressed mainly in epithelial cells. Expressed in the central nervous system (CNS), in the ileum and within the brain in the frontal and occipital lobe|
Provided below are standard protocols that you may find useful for product applications.
TOX3 contains an HMG-box, indicating that it may be involved in bending and unwinding of DNA and alteration of chromatin structure. The C-terminus of the encoded protein is glutamine-rich due to CAG repeats in the coding sequence. A minor allele of this gene has been implicated in an elevated risk of breast cancer.
Wacholder, S., et al. N. Engl. J. Med. 362(11):986-993(2010)
Odefrey, F., et al. Cancer Res. 70(4):1449-1458(2010)
Couch, F.J., et al. Cancer Epidemiol. Biomarkers Prev. 18(11):3044-3048(2009)
Stacey, S.N., et al. Nat. Genet. 39(7):865-869(2007)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.